Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efruxifermin - Akero Therapeutics

Next Previous
Drug Profile

Efruxifermin - Akero Therapeutics

Alternative Names: AKR-001; AMG-876; EFX; Fc-FGF21(RGE)

Latest Information Update: 25 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Akero Therapeutics; Amgen
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Cardiovascular therapies; Fibroblast growth factors; Hepatoprotectants; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase II Liver cirrhosis

Most Recent Events

  • 18 Aug 2025 Efficacy data from a phase IIb HARMONY trial in Non-alcoholic steatohepatitis released by Akero Therapeutics
  • 13 May 2025 Efficacy data from the phase IIb SYMMETRY trial in Non-alcoholic-steatohepatitis released by Akero Therapeutics
  • 09 May 2025 Efficacy data from the phase IIb SYMMETRY trial in Non-alcoholic-steatohepatitis released by Akero Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top